Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

We recently noted that low doses of sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating CD95, and this drug combination is entering phase I trials. The present studies mechanistically extended our initial observations. Low doses of sorafenib and vorinosta...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Park, Margaret A., Zhang, Guo, Martin, Aditi Pandya, Hamed, Hossein, Mitchell, Clint, Hylemon, Philip B., Graf, Martin, Rahmani, Mohamed, Ryan, Kevin, Liu, Xiang, Spiegel, Sarah, Norris, James, Fisher, Paul B., Grant, Steven, Dent, Paul
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2008
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2674577/
https://ncbi.nlm.nih.gov/pubmed/18787411
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk